Physician profile
Daniel D So
NPI 1023167004
$283,075.05
in general payments reported to CMS, 2019-2025
68 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $36K · 2021: $63K · 2022: $41K · 2023: $21K · 2024: $26K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Food and Beverage: $16K · Education: $464 · Travel and Lodging: $451 · Long Term Medical Supply Or Device Loan: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,475.00 |
| Food and Beverage | $15,735.18 |
| Education | $463.54 |
| Travel and Lodging | $450.50 |
| Long Term Medical Supply Or Device Loan | $159.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84,361.75 | 2019-2024 | |
| Lilly USA, LLC | $71,561.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69,767.96 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $19,003.13 | 2019-2023 | Farxiga |
| Abbvie INC. | $17,120.20 | 2019-2025 | Synthroid |
| Dexcom, INC. | $3,238.29 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $1,607.90 | 2019-2025 | Korlym |
| Novo Nordisk INC | $1,565.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,390.09 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx, Freestyle Libre 2 |
| Amgen INC. | $1,314.51 | 2019-2025 | Evenity, Tepezza, Prolia |
| Amneal Pharmaceuticals LLC | $856.76 | 2019-2025 | Unithroid |
| Mannkind Corporation | $818.19 | 2019-2025 | Afrezza |
| Antares Pharma, INC. | $657.57 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Esperion Therapeutics, INC. | $633.20 | 2020-2025 | Nexletol |
| Opko Pharmaceuticals, LLC | $551.73 | 2019-2023 | Rayaldee |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $514.46 | 2020-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $505.26 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $490.12 | 2020-2025 | Recorlev, Keveyis, Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $466.58 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $430.01 | 2023-2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $422.89 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $414.17 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $409.45 | 2019-2023 | Steglatro |
| Horizon Therapeutics Plc | $408.51 | 2019-2023 | Tepezza |
| Madrigal Pharmaceuticals | $347.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $347.69 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inpen Smart Insulin Delivery System |
| Janssen Pharmaceuticals, INC | $323.74 | 2019-2021 | |
| Beta Bionics, INC. | $322.18 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $295.58 | 2019-2022 | |
| Ibsa Pharma INC. | $287.97 | 2019-2025 | Tirosint, Licart, Flector |
| Novartis Pharmaceuticals Corporation | $272.75 | 2024-2025 | |
| Amryt Pharma Holdings Ltd | $262.72 | 2021-2023 | Mycapssa |
| Radius Health, INC. | $180.95 | 2019-2025 | Tymlos |
| Insulet Corporation | $169.21 | 2019-2024 | Omnipod |
| Astellas Pharma US INC | $146.34 | 2023-2025 | Veozah |
| Cequr Corporation | $141.84 | 2023-2024 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $129.90 | 2020-2025 | Isturisa, Signifor Lar |
| Medtronic Minimed, INC. | $113.37 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $99.75 | 2019-2023 | |
| Vivus LLC | $85.02 | 2019-2025 | Qsymia |
| Halozyme INC | $83.24 | 2023 | |
| Kyowa Kirin, INC. | $74.71 | 2023-2024 | Crysvita |
| Shire North American Group INC | $67.34 | 2019 | |
| Nevro Corp. | $65.71 | 2022-2024 | Senza |
| Verity Pharmaceuticals INC. | $65.29 | 2025 | Tlando |
| Lifescan, INC. | $62.16 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $60.32 | 2024-2025 | |
| Rhythm Pharmaceuticals, INC. | $46.80 | 2025 | Imcivree |
| Glaxosmithkline, LLC. | $45.81 | 2025 | Shingrix, Arexvy |
| Ipsen Biopharmaceuticals, INC | $40.70 | 2019-2021 | |
| Echosens North America, INC. | $39.70 | 2023-2025 | Fibroscan, Fibroscan |
| Roche Diabetes Care, INC. | $38.43 | 2020-2021 | |
| Zealand Pharma US, INC. | $36.98 | 2021 | |
| Clarus Therapeutics INC. | $35.55 | 2021 | |
| Azurity Pharmaceuticals, INC. | $34.88 | 2023 | Adthyza |
| Organogenesis INC. | $28.95 | 2021 | |
| Jazz Pharmaceuticals INC. | $28.36 | 2022 | |
| Embecta Corp. | $26.73 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Eisai INC. | $22.91 | 2019 | |
| Becton, Dickinson and Company | $22.16 | 2022 | |
| Companion Medical, INC. | $18.95 | 2019 | |
| Valeritas, INC. | $15.37 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.65 | 2023 | NP Thyroid 60 |
| Chiesi USA, INC. | $14.27 | 2024 | Mycapssa |
| Ionis Pharmaceuticals, INC. | $13.59 | 2025 | Tryngolza |
| Mission Pharmacal Company | $12.02 | 2019 | |
| Theracosbio, LLC | $11.98 | 2024 | Brenzavvy |
| Grt US Holding, INC. | $11.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$375.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.